Onko Logic Surgery: Medical Device Pricing & Revenue Maximization Case Study

Pricing and Revenue Maximization Strategy for a Medical Device in Breast-Conserving Surgery

In this case analysis, I examine Onko Logic Surgery, a fictional medical device company, as an example of a healthcare technology pricing and revenue maximization consulting engagement.

At the center of the case is a new medical device designed to assist surgeons during breast-conserving surgeries. Breast-conserving surgery involves the partial removal of cancerous breast tissue, in contrast to mastectomy, which involves removal of the entire breast.

Onko Logic Surgery has developed a new device for use in this surgical setting. The company is preparing to launch the product in the United States and wants to determine the pricing strategy that maximizes revenue potential.

The central question is:

At what price should Onko Logic Surgery launch this new medical device in the U.S. market?

My approach is not to treat this as a simple question of whether the device should be “expensive” or “affordable.” Instead, I analyze the pricing decision through a structured framework that considers market potential, clinician adoption, price elasticity, revenue potential, competitive risk, and the distinction between revenue maximization and profit maximization.

---

1. Defining the Problem Correctly

The first step is to define the problem Onko Logic Surgery is trying to solve.

This is not primarily a product development problem. The device has already been developed, there are no R&D quality concerns assumed in the case, and the product has regulatory approval. Therefore, the core issue is not whether the device works, but how it should be priced.

The key management question is:

Which price point allows the company to generate the highest potential revenue?

At this stage, several distinctions are important:

• The highest adoption rate does not necessarily produce the highest revenue.
• The highest price does not necessarily produce the highest revenue.
• Revenue maximization is not the same as profit maximization.
• Clinician adoption may be sensitive to price.
• Medical device pricing should be based not only on cost-plus logic, but also on clinical value and willingness to pay.

The key strategic insight is:

For Onko Logic Surgery, the right price must balance clinical adoption potential with the willingness of surgeons and healthcare institutions to pay for the device.

---

2. Determining Market Potential

The second step is to estimate the total market potential for the device.

The case assumes that approximately 100,000 breast-conserving surgeries are performed annually in the United States. The device is applicable across a wide range of procedures and can be used in every breast-conserving surgery.

The device is disposable, meaning each surgery requires a new device.

The annual market potential can therefore be calculated as:

Number of annual surgeries × Number of devices per surgery = Annual device demand potential

100,000 surgeries × 1 device = 100,000 devices

Therefore, the theoretical maximum annual demand for Onko Logic Surgery’s device in the U.S. market is 100,000 units.

The key insight is:

The market potential is limited but clearly defined by procedure volume. Therefore, the pricing strategy should follow the logic of a procedure-based medical device market rather than a broad consumer market.

---

3. Product Characteristics and Clinical Suitability

The third step is to evaluate the clinical and commercial characteristics of the device.

According to the case assumptions, the device has several important advantages:

• It can be used across breast-conserving surgeries.
• It is disposable.
• A new device is required for every surgery.
• It is FDA approved.
• There are no R&D quality concerns.
• The device is assumed to have a complete success rate in the case.
• There are currently no direct competitors.
• It would be the only product of its kind on the market.

These characteristics suggest that the device may have a strong pricing position. The absence of direct competitors particularly increases the company’s pricing power.

However, medical device pricing is not determined by technical strength alone. Surgeon adoption, hospital procurement processes, reimbursement structures, clinical habits, and integration into surgical workflow all matter.

The commercial success of the device therefore depends on three factors:

1. Clinical trust
2. Ease of use
3. Price-adoption balance

The key strategic insight is:

Onko Logic Surgery’s device appears technically strong, but its revenue potential will be determined by how willing clinicians are to adopt it at different price points.

---

4. Analyzing Clinician Adoption

The fourth step is to analyze expected clinician adoption at different price levels.

Market research provides the following adoption expectations:

Price per Device	Expected Share of Surgeries Using the Device
$0	90%
$300	75%
$600	50%
$1,000	10%

This table shows clear price sensitivity. As price increases, adoption decreases. This is expected. The strategic question is not which price produces the highest adoption, but which price produces the highest total revenue.

The important point is:

The highest adoption rate is not necessarily the best pricing strategy.

For example, if the device is free, adoption may reach 90%. However, because the price is $0, total revenue is also $0.

Similarly, if the price is $1,000, unit revenue is high, but adoption drops to 10%, limiting total revenue.

Therefore, the correct analysis must evaluate price and adoption together.

---

5. Revenue Potential Calculation

The fifth step is to calculate potential revenue at each price point.

Formula:

Potential Revenue = Total Market Potential × Adoption Rate × Device Price

Total market potential: 100,000 surgeries per year

Market Potential	Price per Device	Adoption Rate	Potential Revenue
100,000	$0	90%	$0
100,000	$300	75%	$22.5M
100,000	$600	50%	$30.0M
100,000	$1,000	10%	$10.0M

Based on this calculation, the highest potential revenue is generated at the $600 price point.

At $600, the device is expected to be used in 50% of surgeries. This translates into 50,000 devices per year.

50,000 devices × $600 = $30M in potential annual revenue

This analysis indicates that the revenue-maximizing price for Onko Logic Surgery is $600 per device.

The key financial insight is:

Higher adoption does not always create higher revenue. Price and volume must be optimized together.

---

6. Revenue Maximization vs. Profit Maximization

The sixth step is to highlight an important strategic distinction.

This analysis is based on revenue maximization. However, for a company, the ultimate objective is often profit rather than revenue.

The $600 price point generates the highest potential revenue based on the available data. However, whether it also maximizes profit cannot be determined without additional cost information.

The missing critical information includes:

• Manufacturing cost per device
• Packaging cost
• Distribution cost
• Sales and marketing cost
• Clinical training cost
• Hospital contracting cost
• Sales representative cost
• Regulatory and compliance cost
• Warranty, follow-up, and support cost

Therefore, the correct conclusion is:

$600 is the revenue-maximizing price based on the current data, but the company must analyze its cost structure to determine whether it is also the profit-maximizing price.

This distinction is critical in consulting. A price that maximizes revenue may not be the best business decision if costs are high.

---

7. Pricing Strategy

My core pricing recommendation for Onko Logic Surgery is to launch the device in the U.S. market at a $600 list price.

However, medical device pricing is not only about setting a list price. Purchasing decisions are often influenced by hospital systems, surgeons, procurement committees, and group purchasing organizations.

Therefore, the pricing strategy should be multi-layered.

Recommended pricing approach:

• $600 list price
• Limited launch discount for early adopter clinics
• Volume-based pricing for high-volume hospitals
• Training and protocol support
• Pilot programs with strategic clinical centers
• Long-term supply agreements
• Preferred agreements with selected hospital systems
• Potential value-based pricing once real-world evidence is available

The objective is to preserve the $600 price point while increasing adoption.

In other words, the company should not rely only on price reductions to drive adoption. It should increase adoption through clinical trust, training, contracting, and evidence of value.

The key strategic insight is:

Onko Logic Surgery should aim to maintain the $600 price point while increasing adoption above the initial 50% level over time.

---

8. Go-to-Market Strategy

The eighth step is to define how the device should be introduced into the U.S. market.

In medical devices, the go-to-market strategy is as important as the price itself. Even if the device is technically successful, commercial success will be limited if surgeons and hospitals do not integrate it into routine clinical practice.

Recommended go-to-market strategy:

1. Start with reference centers

The initial launch should focus on high-volume breast surgery centers and academic hospitals.

Objectives:

• Build clinical trust
• Create reference users
• Collect real-world usage data
• Demonstrate integration into the surgical workflow

2. Surgeon-focused training

Surgeons must understand, use, and experience the value of the device.

Recommended initiatives:

• Live training sessions
• Surgical simulation workshops
• Usage protocol guides
• Case sharing by early adopter surgeons
• Presence at clinical congresses and symposia

3. Value communication for hospital procurement committees

Medical device purchasing decisions are influenced not only by clinical value but also by economic value.

The value proposition should include:

• Procedure standardization
• Ease of use
• Support for surgical workflow
• Clinical reliability
• Workflow integration
• Potential efficiency contribution

4. Contracting and channel strategy

To accelerate adoption, the company should build relationships with hospital networks and large health systems.

Recommended actions:

• Agreements with major hospital groups
• Discussions with group purchasing organizations
• Volume-based contracts
• Long-term supply agreements after pilot use

This go-to-market strategy supports both clinical and commercial adoption.

---

9. Prioritizing the Strategies

Not all actions should be implemented at once. The strategies should be prioritized based on impact, difficulty, timing, and risk.

Strategy	Impact	Difficulty	Timing	Risk	Recommendation
$600 list price	High	Low	Short term	Medium	Implement
Pilot use in reference clinics	High	Medium	Short term	Low-medium	Prioritize
Surgeon training program	High	Medium	Short to medium term	Low	Implement
Volume-based hospital contracts	Medium-high	Medium	Medium term	Medium	Plan
Patent and IP protection	Very high	Medium	Short to medium term	Low	Prioritize
Agreements with purchasing organizations	High	High	Medium term	Medium	Evaluate
Value-based pricing	Medium-high	High	Long term	Medium-high	Evaluate after data
International expansion	High	High	Long term	High	Consider after U.S. launch

The first stage should focus on:

• Using $600 as the base price
• Launching in reference clinics
• Building surgeon training infrastructure
• Strengthening intellectual property protection
• Collecting cost data to complete profit maximization analysis

---

10. Risks

The case presents a strong commercial opportunity, but several risks must be managed.

Key risks include:

• Competitors may develop similar devices
• Patent protection may be insufficient
• Some clinics may perceive $600 as too expensive
• Adoption may be lower than expected
• Hospital procurement cycles may be slow
• Reimbursement dynamics may not support the price
• Surgeons may be reluctant to change existing practices
• The revenue-maximizing price may not be the profit-maximizing price
• Manufacturing and distribution costs may be higher than expected
• Training requirements may slow the sales process

Therefore, the pricing decision should be supported by controlled launch execution and ongoing market feedback.

---

11. Next Steps

My recommended next steps for Onko Logic Surgery are as follows:

1. Complete the cost analysis

The revenue analysis points to $600 as the optimal price. However, the company must calculate all cost components to determine the profit-maximizing price.

2. Strengthen patents and barriers to entry

The absence of competitors is a major advantage, but it must be protected.

Recommended actions:

• Patent filings
• Protection of design and usage protocols
• Preferred-use agreements with clinical centers
• Distribution and supply agreements

3. Run a pilot launch

The device should first be tested in high-volume centers with trusted clinicians.

4. Track real adoption data

The company should monitor adoption at the $600 price point in the real market.

Key metrics:

• Utilization rate
• Hospital acceptance rate
• Surgeon satisfaction
• Procurement cycle length
• Gross margin per device
• Repeat order rate
• Training requirement
• Integration into clinical workflow

5. Segment pricing if necessary

If willingness to pay differs across hospital types, pricing can be segmented.

Potential segments:

• Academic medical centers
• High-volume cancer centers
• Community hospitals
• Large hospital systems
• Early adopter clinics
• High-volume purchasing institutions

This allows the company to move beyond a rigid single-price model and adopt a more strategic pricing approach.

---

12. Consulting Perspective: Core Strategic Insight

This case demonstrates a fundamental principle in medical device pricing:

The highest clinical adoption rate is not always the best commercial strategy. The right price is found at the point where clinical willingness to adopt and revenue potential are optimized together.

For Onko Logic Surgery, a $0 price creates high adoption but no revenue. A $1,000 price creates high unit revenue but very low adoption. The $600 price point provides the strongest balance between price and volume.

Therefore, my strategic recommendation is:

Launch the device at $600 per unit, while continuously testing the decision against cost structure, profit margin, hospital procurement behavior, and real-world adoption data.

---

Conclusion: Strategic Recommendation for Onko Logic Surgery

My final recommendation for Onko Logic Surgery is to launch the device in the U.S. market at a $600 unit price.

The rationale is as follows:

1. The market potential is clearly defined.
There are approximately 100,000 breast-conserving surgeries per year in the United States, and the device can be used in each procedure.

2. The device is disposable.
Each surgery requires a new device, creating recurring demand linked to procedure volume.

3. The price-adoption analysis points to $600.
At $300, adoption is higher, but total revenue is $22.5M. At $600, adoption falls to 50%, but total revenue increases to $30M.

4. The $1,000 price point is too aggressive.
At this price, adoption falls to 10%, limiting revenue to $10M.

5. The absence of competition is a strong opportunity.
However, this advantage should be protected through patents, clinical relationships, and contracts.

Overall, the best strategy for Onko Logic Surgery is to enter the market at the $600 revenue-maximizing price point, support early clinical adoption, strengthen intellectual property barriers, and complete the cost analysis required for profit maximization.

This case highlights a fundamental truth in healthcare technology consulting:

Medical device pricing is not just about setting a price. It requires the integrated analysis of clinical value, adoption behavior, market size, competitive barriers, and profitability.